Biosimilars are not just about savings. More manufacturers can mean innovation: better programs/devices pursuing new indications eg COVID sc formulations CT-P13 infliximab biosimilar: immunogenicity sc vs iv same. Particularly useful in pandemic times! #ACR20 ABST1208 @RheumNow https://t.co/WjJ6OOST55